News

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

Garimella discusses the history, clinical impact, and rationale for removing race-based GFR from clinical decision-making.